Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jounce Therapeutics Inc (JNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,832
  • Shares Outstanding, K 32,480
  • Annual Sales, $ 71,640 K
  • Annual Income, $ -16,440 K
  • 36-Month Beta 5.55
  • Price/Sales 3.59
  • Price/Cash Flow N/A
  • Price/Book 2.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.92 +17.77%
on 06/04/18
11.85 -31.22%
on 05/24/18
-2.45 (-23.11%)
since 05/21/18
3-Month
6.92 +17.77%
on 06/04/18
25.79 -68.40%
on 03/22/18
-17.40 (-68.10%)
since 03/21/18
52-Week
6.92 +17.77%
on 06/04/18
29.25 -72.14%
on 03/13/18
-7.59 (-48.22%)
since 06/21/17

Most Recent Stories

More News
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a stock index of top companies developing...

CLDX : 0.56 (-4.00%)
JNCE : 8.15 (-2.98%)
IDRA : 1.47 (-3.92%)
RCUS : 16.02 (-1.48%)
BLCM : 7.64 (-6.14%)
INO : 4.19 (-3.68%)
FATE : 13.08 (-2.97%)
MRTX : 52.40 (+1.75%)
SRNE : 6.15 (-7.52%)
MOR : 30.22 (+0.13%)
AGEN : 2.50 (-9.75%)
INCY : 72.49 (-1.28%)
ZYME : 16.11 (-2.72%)
NK : 2.83 (+3.66%)
PIRS : 5.21 (-3.34%)
NLNK : 5.16 (-2.27%)
Cancer Treatment Breakthroughs Providing Boost for Biotech Market

MarketNewsUpdates.com News Commentary

SGMO : 16.13 (-10.64%)
JNCE : 8.15 (-2.98%)
ABEO : 15.80 (-4.53%)
MBRX : 1.87 (-13.82%)
NKTR : 55.86 (-3.97%)
BMY : 53.94 (-0.57%)
Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic Software Enterprises, Jounce Therapeutics, and Akebia Therapeutics -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Core-Mark Holding Company,...

CORE : 22.57 (+0.71%)
MGIC : 8.20 (-1.80%)
JNCE : 8.15 (-2.98%)
AKBA : 10.84 (-4.41%)
IRTC : 78.92 (-2.08%)
SSRM : 9.80 (+2.08%)
Today's Research Reports on Stocks to Watch: Deciphera Pharmaceuticals and Jounce Therapeutics

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own...

JNCE : 8.15 (-2.98%)
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today presented preliminary data from...

JNCE : 8.15 (-2.98%)
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts

JNCE : 8.15 (-2.98%)
Jounce Therapeutics Reports First Quarter 2018 Financial Results

- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting -

JNCE : 8.15 (-2.98%)
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference

Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced...

JNCE : 8.15 (-2.98%)
DB : 10.89 (-1.71%)
New Research Coverage Highlights YY, Orbotech, Green Plains Partners LP, Jounce Therapeutics, Carbonite, and Golar LNG Partners LP -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of YY Inc. (NASDAQ:YY), Orbotech...

YY : 112.02 (-1.74%)
CARB : 38.15 (-2.80%)
JNCE : 8.15 (-2.98%)
GPP : 17.25 (-0.86%)
ORBK : 63.11 (+0.43%)
GMLP : 15.50 (-0.90%)
Report: Exploring Fundamental Drivers Behind Gladstone Commercial, IRHYTHM TECH, Jounce Therapeutics, CoStar Group, Tecnoglass, and Merus N.V -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Gladstone Commercial Corporation...

JNCE : 8.15 (-2.98%)
CSGP : 415.09 (-0.52%)
MRUS : 22.47 (-0.09%)
IRTC : 78.92 (-2.08%)
GOOD : 18.85 (-0.21%)
TGLS : 8.75 (+0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNCE with:

Business Summary

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator,...

See More

Key Turning Points

2nd Resistance Point 9.12
1st Resistance Point 8.64
Last Price 8.15
1st Support Level 7.81
2nd Support Level 7.46

See More

52-Week High 29.25
Fibonacci 61.8% 20.72
Fibonacci 50% 18.08
Fibonacci 38.2% 15.45
Last Price 8.15
52-Week Low 6.92

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar